{"id":"gnrh-agonist-triptorelin","safety":{"commonSideEffects":[{"rate":"50–80","effect":"Hot flashes"},{"rate":"30–50","effect":"Erectile dysfunction"},{"rate":"30–50","effect":"Decreased libido"},{"rate":"5–15","effect":"Injection site reactions"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"5–10","effect":"Gynecomastia"},{"rate":"5–20","effect":"Tumor flare (initial testosterone surge)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triptorelin binds to GnRH receptors on pituitary gonadotroph cells, triggering an initial surge in LH and FSH release. With continuous exposure, the pituitary becomes desensitized, leading to downregulation of GnRH receptors and sustained suppression of gonadal sex hormone production. This mechanism is exploited therapeutically to reduce testosterone in prostate cancer and estrogen in hormone-sensitive breast cancer, or to suppress puberty progression in precocious puberty.","oneSentence":"Triptorelin is a GnRH agonist that stimulates the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, initially increasing sex hormone levels before causing desensitization and suppression of testosterone and estrogen production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:12.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Hormone-sensitive breast cancer"},{"name":"Precocious puberty"},{"name":"Endometriosis"}]},"trialDetails":[{"nctId":"NCT06832774","phase":"PHASE2","title":"Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-01","conditions":"Prostate Cancer Metastatic Disease","enrollment":192},{"nctId":"NCT07319429","phase":"PHASE2, PHASE3","title":"Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Endometrial Cancer, Fertility","enrollment":260},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":"Prostatic Neoplasms","enrollment":693},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":1538},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":239},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT07254429","phase":"PHASE2","title":"COMPASS - COpenhagen MenoPAuSe Study","status":"RECRUITING","sponsor":"Martin Blomberg Jensen","startDate":"2025-10-02","conditions":"Menopausal Osteoporosis, Bone Markers","enrollment":192},{"nctId":"NCT03332797","phase":"PHASE1","title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2017-11-24","conditions":"Breast Cancer","enrollment":181},{"nctId":"NCT00066703","phase":"PHASE3","title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":2672},{"nctId":"NCT00066690","phase":"PHASE3","title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-12-17","conditions":"Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma","enrollment":3066},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mCRPC","enrollment":10},{"nctId":"NCT06913075","phase":"NA","title":"FET in Adenomyosis","status":"NOT_YET_RECRUITING","sponsor":"Indira IVF Hospital Pvt Ltd","startDate":"2026-06-25","conditions":"Adenomyosis","enrollment":700},{"nctId":"NCT05498272","phase":"PHASE2","title":"Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations","status":"RECRUITING","sponsor":"Rana McKay, MD","startDate":"2023-02-01","conditions":"Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation","enrollment":32},{"nctId":"NCT07242534","phase":"PHASE4","title":"Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","status":"RECRUITING","sponsor":"Fundacion Dexeus","startDate":"2026-01-19","conditions":"Infertility, Obesity","enrollment":62},{"nctId":"NCT04356664","phase":"PHASE2, PHASE3","title":"Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2021-03-18","conditions":"Endometriosis, Adenomyosis, Infertility, Female","enrollment":180},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT05746806","phase":"NA","title":"Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-29","conditions":"Recurrent Prostate Cancer","enrollment":36},{"nctId":"NCT03809000","phase":"PHASE2","title":"A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2019-04-15","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT01492972","phase":"PHASE3","title":"Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2012-01","conditions":"Prostate Cancer","enrollment":192},{"nctId":"NCT06150703","phase":"PHASE3","title":"Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-27","conditions":"In Vitro Fertilization, ICSI Intracytoplasmic Spermatozoid Injection","enrollment":652},{"nctId":"NCT07128394","phase":"NA","title":"Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment","status":"RECRUITING","sponsor":"Nanjing University","startDate":"2024-02-01","conditions":"Infertility, Female, Luteinizing Hormone (LH)","enrollment":590},{"nctId":"NCT04181203","phase":"PHASE3","title":"Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-01-09","conditions":"Prostate Cancer","enrollment":490},{"nctId":"NCT05458856","phase":"PHASE3","title":"Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-08-30","conditions":"Prostate Cancer","enrollment":147},{"nctId":"NCT00963417","phase":"NA","title":"Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2009-08-03","conditions":"Breast Cancer, Osteoporosis","enrollment":119},{"nctId":"NCT01673984","phase":"PHASE4","title":"GP Extended Action Triptorelin","status":"TERMINATED","sponsor":"Ipsen","startDate":"2012-08","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT00567580","phase":"PHASE3","title":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-02","conditions":"Prostate Cancer","enrollment":1792},{"nctId":"NCT06225284","phase":"PHASE2","title":"Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-08-22","conditions":"Triple Negative Breast Cancer, Premenopausal Breast Cancer","enrollment":124},{"nctId":"NCT02346253","phase":"NA","title":"High-Dose Brachytherapy in Treating Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2015-01-13","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":146},{"nctId":"NCT03944434","phase":"PHASE2","title":"FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":116},{"nctId":"NCT06763926","phase":"PHASE4","title":"Intranasal Nafarelin For Triggering Oocyte Maturation","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Dexeus","startDate":"2025-03-15","conditions":"Fertility Disorders","enrollment":134},{"nctId":"NCT05286554","phase":"PHASE4","title":"Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-03-17","conditions":"Female Infertility","enrollment":75},{"nctId":"NCT02588404","phase":"","title":"The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient","status":"WITHDRAWN","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2015-12","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT04992026","phase":"PHASE2","title":"The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-01-01","conditions":"Prostatectomy, Oligometastatic Prostate Cancer, Abiraterone","enrollment":130},{"nctId":"NCT02685397","phase":"PHASE2, PHASE3","title":"Management of Castration-Resistant Prostate Cancer with Oligometastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2016-10","conditions":"Castration-resistant Prostate Cancer Patients with Oligometastases","enrollment":102},{"nctId":"NCT06525155","phase":"PHASE3","title":"Effect GnRH Agonist Administration in Endometriosis Cyst Patients","status":"RECRUITING","sponsor":"Rumah Sakit Pusat Angkatan Darat Gatot Soebroto","startDate":"2024-01-02","conditions":"Endometriosis","enrollment":32},{"nctId":"NCT06691815","phase":"NA","title":"Triptorelin for Early Diagnosis of Hypogonadotrophic Hypogonadism","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital de Niños R. Gutierrez de Buenos Aires","startDate":"2022-08-01","conditions":"Pubertal Delay, Hypogonadism, Hypogonadotropic, Constitutional Delay in Growth and Puberty (CDGP)","enrollment":48},{"nctId":"NCT06581679","phase":"NA","title":"Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2023-12-15","conditions":"Adenomyosis","enrollment":184},{"nctId":"NCT02400801","phase":"NA","title":"Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-06","conditions":"Endometriosis, Infertility","enrollment":166},{"nctId":"NCT03311555","phase":"PHASE2","title":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2018-03-28","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT03899077","phase":"PHASE2","title":"Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP","status":"UNKNOWN","sponsor":"Cancer Research Antwerp","startDate":"2019-04-05","conditions":"Cancer of Prostate","enrollment":202},{"nctId":"NCT05567731","phase":"NA","title":"Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-15","conditions":"Intracytoplasmic Sperm Injection, GnRH Agonist, Infertility","enrollment":30},{"nctId":"NCT06146413","phase":"PHASE2","title":"Triggering Oocyte Maturation in Normoresponders Using Double Trigger or HCG Trigger","status":"UNKNOWN","sponsor":"Bedaya Hospital","startDate":"2023-12-30","conditions":"Infertility","enrollment":150},{"nctId":"NCT05781217","phase":"PHASE3","title":"Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624","status":"RECRUITING","sponsor":"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","startDate":"2023-03-14","conditions":"Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence","enrollment":534},{"nctId":"NCT02330770","phase":"PHASE4","title":"Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2016-06-06","conditions":"Infertility","enrollment":225},{"nctId":"NCT02312076","phase":"PHASE4","title":"GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2016-09-09","conditions":"Infertility","enrollment":200},{"nctId":"NCT02312089","phase":"PHASE4","title":"GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2016-08-07","conditions":"Infertility","enrollment":200},{"nctId":"NCT04724486","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI","status":"COMPLETED","sponsor":"Damascus University","startDate":"2020-08-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50},{"nctId":"NCT04724343","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.","status":"COMPLETED","sponsor":"Damascus University","startDate":"2019-12-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50},{"nctId":"NCT04727684","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI","status":"COMPLETED","sponsor":"Damascus University","startDate":"2020-08-22","conditions":"In Vitro Fertilization, Infertility, Intracytoplasmic Sperm Injection","enrollment":50},{"nctId":"NCT04727671","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.","status":"COMPLETED","sponsor":"Damascus University","startDate":"2019-12-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50},{"nctId":"NCT05972902","phase":"PHASE3","title":"Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-07-15","conditions":"IVF","enrollment":387},{"nctId":"NCT00840944","phase":"PHASE4","title":"A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height","status":"UNKNOWN","sponsor":"Belgian Study Group for Pediatric Endocrinology","startDate":"2008-01","conditions":"Idiopathic Short Stature","enrollment":44},{"nctId":"NCT03169166","phase":"PHASE4","title":"The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2017-03-01","conditions":"Sterility, Infertility","enrollment":277},{"nctId":"NCT04157725","phase":"PHASE4","title":"Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization","status":"UNKNOWN","sponsor":"American University of Beirut Medical Center","startDate":"2023-06-01","conditions":"PCO - Polycystic Ovaries, Infertility","enrollment":154},{"nctId":"NCT05945407","phase":"NA","title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2016-08-01","conditions":"Endometrial Neoplasms, Endometrial Neoplasm Malignant, Endometrial Neoplasm Malignant Stage I","enrollment":57},{"nctId":"NCT04549649","phase":"NA","title":"The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2019-11-01","conditions":"Ovarian Stimulation, Reproductive Techniques, Assisted","enrollment":52},{"nctId":"NCT04586686","phase":"NA","title":"Combining Interventions of Fertility Preservation to Mitigate Fertility Loss After Breast Cancer","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-11-01","conditions":"Breast Cancer Female","enrollment":41},{"nctId":"NCT04616729","phase":"PHASE1, PHASE2","title":"DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-11-01","conditions":"Breast Cancer Female","enrollment":30},{"nctId":"NCT05801705","phase":"","title":"Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk","enrollment":700},{"nctId":"NCT04446845","phase":"PHASE4","title":"Double Stimulation Followed by a Fresh Embryo Transfer","status":"COMPLETED","sponsor":"Fundación Santiago Dexeus Font","startDate":"2020-10-30","conditions":"Infertility","enrollment":120},{"nctId":"NCT04071574","phase":"PHASE1, PHASE2","title":"Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility","status":"COMPLETED","sponsor":"Lebanese University","startDate":"2018-02-01","conditions":"Female Infertility, Female Infertility Due to Ovulatory Disorder, Premature Ovarian Failure","enrollment":200},{"nctId":"NCT05019846","phase":"PHASE3","title":"SRT Versus SRT+ADT in Prostate Cancer","status":"RECRUITING","sponsor":"Marco Lorenzo Bonu","startDate":"2021-09-30","conditions":"Prostate Cancer","enrollment":310},{"nctId":"NCT05800197","phase":"","title":"Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2014-04-15","conditions":"Breast Cancer, Neoadjuvant Endocrine Therapy","enrollment":300},{"nctId":"NCT04600986","phase":"NA","title":"Repeated Doses of GnRH Agonist as Oocyte Triggering in Antagonist Protocol for Patients With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2020-05-30","conditions":"Polycystic Ovary Syndrome","enrollment":70},{"nctId":"NCT03940807","phase":"PHASE3","title":"Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI in Adenomyosis","status":"WITHDRAWN","sponsor":"University Hospital, Toulouse","startDate":"2022-04-29","conditions":"Adenomyosis","enrollment":""},{"nctId":"NCT03349905","phase":"NA","title":"Deferred Versus Fresh Embryo Transfers","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-24","conditions":"Infertility, Female","enrollment":237},{"nctId":"NCT02113553","phase":"PHASE2","title":"Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve","status":"TERMINATED","sponsor":"Armando Santoro, MD","startDate":"2013-05","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT03279250","phase":"PHASE2","title":"Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8","enrollment":86},{"nctId":"NCT03660813","phase":"NA","title":"Follicle Size and Oocyte Development","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2018-07-01","conditions":"IVF Treatment","enrollment":200},{"nctId":"NCT05397795","phase":"PHASE3","title":"COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-06-01","conditions":"Infertility","enrollment":160},{"nctId":"NCT04087408","phase":"PHASE3","title":"Role of Triptorelin 0.1 mg as a Luteal Phase Support in Assisted Reproductive Technique After Embryo Transfer : a Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Moustafa Mohammed Abouelea","startDate":"2020-04-01","conditions":"Effect of Adding GnRHa as Luteal Phase Support in Antagonist ART Cycles","enrollment":150},{"nctId":"NCT04846218","phase":"NA","title":"Agonist Trigger With HCG Luteal Supplementation vs HCG Trigger With Progesterone Luteal Supplementation in Antagonist Controlled HyperstimulationCycle","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2016-12","conditions":"Infertility, Female","enrollment":100},{"nctId":"NCT04854707","phase":"","title":"An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data","status":"COMPLETED","sponsor":"IVFarma LLC","startDate":"2020-01-12","conditions":"Reproductive Issues, Reproductive Disorder, Fertility Disorders","enrollment":5484},{"nctId":"NCT04248621","phase":"PHASE4","title":"Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients","status":"UNKNOWN","sponsor":"Wonju Severance Christian Hospital","startDate":"2020-01-23","conditions":"Prostatic Neoplasms","enrollment":164},{"nctId":"NCT04224818","phase":"PHASE3","title":"Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2018-07-11","conditions":"Poor Ovarian Reserve","enrollment":140},{"nctId":"NCT04973969","phase":"NA","title":"Follicular Challenge Test to Predict Response to GnRH Agonist Triggering","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2021-01-01","conditions":"Infertility, Female","enrollment":100},{"nctId":"NCT04454749","phase":"","title":"Endometrial Compaction and Its Influence on Pregnancy Rate in Frozen Embryo Cycle Regimes","status":"TERMINATED","sponsor":"ART Fertility Clinics LLC","startDate":"2020-11-09","conditions":"Endometrial Disorder, Infertility, Female, IVF","enrollment":3},{"nctId":"NCT04749979","phase":"NA","title":"Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin","status":"UNKNOWN","sponsor":"Aljazeera Hospital","startDate":"2021-02-05","conditions":"Infertility","enrollment":100},{"nctId":"NCT00090844","phase":"PHASE2","title":"Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer","status":"TERMINATED","sponsor":"University of South Florida","startDate":"2004-07","conditions":"Breast Cancer, Hormone Changes, Drug Toxicity","enrollment":49},{"nctId":"NCT03536234","phase":"PHASE2","title":"Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"Immune System Regulation AB","startDate":"2018-09-19","conditions":"HIV-1-infection","enrollment":52},{"nctId":"NCT01278290","phase":"PHASE3","title":"Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls","status":"COMPLETED","sponsor":"Hospital de Niños R. Gutierrez de Buenos Aires","startDate":"2009-12","conditions":"Central Precocious Puberty, Sexual Precocity","enrollment":46},{"nctId":"NCT03291821","phase":"NA","title":"DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore","status":"COMPLETED","sponsor":"IVI Madrid","startDate":"2017-12-01","conditions":"Infertility, Female","enrollment":136},{"nctId":"NCT04659551","phase":"PHASE2","title":"Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2017-10-05","conditions":"Breast Cancer","enrollment":43},{"nctId":"NCT00004054","phase":"PHASE3","title":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-01","conditions":"Prostate Cancer","enrollment":397},{"nctId":"NCT02742675","phase":"PHASE2","title":"Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2015-09","conditions":"Prostate Cancer","enrollment":200},{"nctId":"NCT04407065","phase":"PHASE2","title":"Double Trigger in Patients With Low Number of Oocytes Retrieved Per Number of Preovulatory Follicles","status":"UNKNOWN","sponsor":"Riyadh Fertility and Reproductive Health center","startDate":"2020-05-30","conditions":"Infertility, Female","enrollment":56},{"nctId":"NCT04407052","phase":"PHASE2","title":"Double Trigger in Patients With Low Proportion of Mature Oocytes","status":"UNKNOWN","sponsor":"Riyadh Fertility and Reproductive Health center","startDate":"2020-05-30","conditions":"Infertility, Female","enrollment":66},{"nctId":"NCT01790126","phase":"PHASE2","title":"The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-03-04","conditions":"Prostate Cancer","enrollment":90},{"nctId":"NCT03115307","phase":"PHASE4","title":"Luteal Phase Support in Insemination Cycles","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2017-01","conditions":"Infertility, Female","enrollment":167},{"nctId":"NCT02856048","phase":"PHASE2, PHASE3","title":"Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-11-23","conditions":"Cancer, Toxicity Due to Chemotherapy, Sarcoma","enrollment":11},{"nctId":"NCT04174378","phase":"","title":"Luteal Phase Support In IVF Women Using GnRH Agonist","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2018-11-29","conditions":"IVF, Luteal Phase Defect","enrollment":222},{"nctId":"NCT00415246","phase":"PHASE3","title":"Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer","status":"TERMINATED","sponsor":"Ipsen","startDate":"2006-11","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT02821819","phase":"PHASE4","title":"Random-start Ovarian Stimulation in Egg-donors (ROSE)","status":"TERMINATED","sponsor":"Instituto Bernabeu","startDate":"2017-01-10","conditions":"Infertility","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":82,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GnRH agonist (triptorelin)","genericName":"GnRH agonist (triptorelin)","companyName":"Taipei Veterans General Hospital, Taiwan","companyId":"taipei-veterans-general-hospital-taiwan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triptorelin is a GnRH agonist that stimulates the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, initially increasing sex hormone levels before causing desensitization and suppression of testosterone and estrogen production. Used for Advanced prostate cancer, Hormone-sensitive breast cancer, Precocious puberty.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}